First Horizon Advisors, Inc. Celldex Therapeutics, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
A detailed history of First Horizon Advisors, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 1,195 shares of CLDX stock, worth $25,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,195
Previous 333
258.86%
Holding current value
$25,620
Previous $6,000
300.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CLDX
# of Institutions
195Shares Held
69.4MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$179 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$139 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$101 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$83.6 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$80.5 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...